Drug development research agreement leverages simulation platform

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ Azri Suratmin)
(Image: Getty/ Azri Suratmin)

Related tags: Research, Simulation, Drug development, Drug development process, Translational medicine, Biology, Antibody drug conjugates

Drug development advisory firm Rosa & Co. enters research agreement with Chugai pharmaceutical to provide access to PhysioPD research services for translational biology.

Chugai, a member of the Roche group, will receive access to Rosa’s research and development services, PhysioPD, a quantitative systems pharmacology approach to translate biology into an interactive simulation platform. The approach translates biology into an interactive simulation platform to represent physiology, disease, and intervention effects.

Per the collaboration, Chugai will use this service across multiple therapeutic areas on its research and development pipeline to discover actionable program recommendations to reduce risk and address consequential decisions regarding drug development.

Rosa and Chugai have engaged in projects together in the past. “We are extremely pleased to extend our relationship with Chugai. Over the last several years we have been working with them on various projects and this agreement validates the value PhysioPD Research brings,”​ Ron Beaver, founder and CEO of Rosa, said in a statement.

Chugai launched the first antibody-drug created in Japan in the 1990s and is currently focused on its proprietary antibody engineering technologies for antibody drug development.

Kimio Terao, department manager of clinical pharmacology and translational research at Chugai, said in a statement, “Chugai strives to develop hand in hand with society through the creation of innovative drugs and services. I am convinced that Rosa's novel platform will provide a powerful tool to transform our research into real innovation.”

Related news

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

Syne Qua Non Clinical | 16-May-2018 | Business Advice

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers

Follow us

Featured Events

View more


View more